These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial. Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399 [TBL] [Abstract][Full Text] [Related]
4. The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment. Gebara MA; Kasckow J; Smagula SF; DiNapoli EA; Karp JF; Lenze EJ; Mulsant BH; Reynolds CF J Psychiatr Res; 2018 Jan; 96():162-166. PubMed ID: 29069615 [TBL] [Abstract][Full Text] [Related]
5. Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression. Waterman L; Stahl ST; Buysse DJ; Lenze EJ; Blumberger D; Mulsant B; Butters M; Gebara MA; Reynolds CF; Karp JF Depress Anxiety; 2016 Dec; 33(12):1107-1113. PubMed ID: 27636232 [TBL] [Abstract][Full Text] [Related]
6. Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment. Saade YM; Nicol G; Lenze EJ; Miller JP; Yingling M; Wetherell JL; Reynolds CF; Mulsant BH Depress Anxiety; 2019 Dec; 36(12):1125-1134. PubMed ID: 31682328 [TBL] [Abstract][Full Text] [Related]
7. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
8. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291 [TBL] [Abstract][Full Text] [Related]
9. Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome. Diniz BS; Mulsant BH; Reynolds CF; Blumberger DM; Karp JF; Butters MA; Mendes-Silva AP; Vieira EL; Tseng G; Lenze EJ JAMA Netw Open; 2022 Jun; 5(6):e2219678. PubMed ID: 35771573 [TBL] [Abstract][Full Text] [Related]
10. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History. Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575 [TBL] [Abstract][Full Text] [Related]
11. Vortioxetine for depression in adults. Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Lyndon GJ; Prieto R; Wajsbrot DB; Allgulander C; Bandelow B Int Clin Psychopharmacol; 2019 May; 34(3):110-118. PubMed ID: 30870236 [TBL] [Abstract][Full Text] [Related]
14. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180 [TBL] [Abstract][Full Text] [Related]
15. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298 [TBL] [Abstract][Full Text] [Related]
16. Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial. Hall CA; Simon KM; Lenze EJ; Dew MA; Begley A; Butters MA; Blumberger DM; Stack JA; Mulsant B; Reynolds CF Psychiatr Serv; 2015 Dec; 66(12):1303-11. PubMed ID: 26278231 [TBL] [Abstract][Full Text] [Related]
17. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
18. Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance. Mulvahill JS; Nicol GE; Dixon D; Lenze EJ; Karp JF; Reynolds CF; Blumberger DM; Mulsant BH J Am Geriatr Soc; 2017 Dec; 65(12):2651-2658. PubMed ID: 29235659 [TBL] [Abstract][Full Text] [Related]
19. Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression. Karim HT; Wang M; Andreescu C; Tudorascu D; Butters MA; Karp JF; Reynolds CF; Aizenstein HJ Neuroimage Clin; 2018; 19():831-839. PubMed ID: 30013927 [TBL] [Abstract][Full Text] [Related]
20. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]